SCD1 can reduce fatty acid oxidation and increase lipid synthesis and ferroptosis resistance, thereby promoting cancer cell growth.[11, 12, 13] Moreover, SCD1 inhibitors can delay Enz resistance and PCa progression.[14] In addition, cluster of differentiation 36 (CD36) is reportedly overexpressed in tumors and is associated with malignant progression and metastasis. Here, CD36 is linked to posterior cortical atrophy.